The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets

Launched by WAEL ELBANNA CLINIC · Feb 23, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different medications, Terlipressin and Carbetocin, on blood loss and hemoglobin levels in women undergoing open myomectomy surgery, which is a procedure to remove fibroids from the uterus. The goal is to see which medication is more effective in reducing blood loss during the surgery when no special tools (called haemostatic tourniquets) are used. This information could help doctors make better decisions and improve care for women with fibroids.

To participate in this trial, women aged 16 to 45 who have myoma-related symptoms like pelvic pain or heavy periods may be eligible. They should be in good health for surgery and have a certain level of hemoglobin in their blood. However, those who have had previous surgeries for fibroids, certain health issues, or are pregnant cannot take part. If you join the study, you will receive one of the two medications before your surgery, and researchers will monitor your blood loss and hemoglobin levels to see how well each medication works. This trial aims to provide valuable information for both doctors and women considering this type of surgery.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteri
• • Women aged 16-45 yearsAppropriate medical status for open surgery (Largest Myoma size from 4 cm up to 20 cm)
• • Baseline hemoglobin ≥9 g/dl
• • No contra-indications to the use of glyopressin or carbitocin
• • Myoma-related symptoms, such as pelvic pressure or pain,menorrhagia, or infertility
• • Not pregnant at the time of presentation (i.e., negative urine pregnancy test or last menstrual period within the last 4 weeks)
• • Exclusion Criteria
• • Open myomectomy using mechanical tourniquet
• • Previous myomectomy
• • History of bleeding disorders
• • Concurrent anticoagulation therapy
• • History of Uncontrolled ischaemic heart disease
• • Any pelvic abnormalities requiring concomitant surgery
• • Treatment with a GnRH agonist or ulipristal acetate within three months preceding surgery
• • Inability to understand and provide written informed consent